USD 27.3 Billion
Biosimilars Market Size, Share, and Growth Analysis
Biosimilars Market By Drug Type (Monocional Antibodies, Insulin, Recombinant Human Growth Hormone), By Indication (Oncology, Inflammatory & Autoimmune Disorders, Chronic Diseases, Blood Disorders), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35H2167 |
Region:
Global |
Published Date: August, 2024
Pages:
165
|Tables:
70
|Figures:
75
Format -
Biosimilars Market Insights
Global Biosimilars Market size was valued at USD 11.39 Billion in 2023 poised to grow from USD 13.15 Billion in 2024 to USD 41.63 Billion by 2032, growing at a CAGR of 15.49% in the forecast period (2025-2032).
The global biosimilars market growth is mainly driven by the patent loss of biologic drugs as more affordable versions of the drug comes up. For example, patent expiration of popular biologics such as Humira (adalimumab), Remicade (infliximab), and Herceptin (trastuzumab) has triggered the lift-off of biosimilar approvals and launches globally. This is translated to huge cost savings for patients and healthcare systems, as these are normally priced 15-30% cheaper than their reference biologics. Lower cost promotes increased adoption levels, particularly in markets that could not afford biologics prior to the present.
The governments and healthcare systems are saving costs while advocating for biosimilar uptake with their reimbursement policies and substitution frameworks. For instance, finance minister of India, Nirmala Sitharaman, on 1 February 2025, widened the list of life-saving medicines exempted from Basic Customs Duty (BCD) to add advanced medicines for cancer, orphan diseases, and immune disorders with an aim to reducing the burden on patients and widening the availability of critical drugs Thus, boosting the biosimilars market growth at an accelerated pace.
One of the driving factors for biosimilars industry is support from regulatory agencies and streamlined approval procedures such as Biologics Price Competition and Innovation Act (BPCIA) and 351(k) Biologics License Application (BLA). As a response to increasing demand for affordable biologic substitutes, agencies such as the U.S. FDA, European Medicines Agency (EMA), and the WHO have created regulatory frameworks to make biosimilar approval quicker and more efficient.
For instance, the FDA's Biologics Price Competition and Innovation Act (BPCIA) offers biosimilars an abbreviated licensure pathway, lowering the cost of development and time-to-market. In the same vein, the EMA's customized guidelines enable them to skip some of the preclinical trials if they show equivalence to the reference biologics. This means, instead of conducting all standard preclinical tests from scratch, they only need to provide sufficient evidence that they match the reference biologic in terms of safety, efficacy, and quality.
This simplified regulatory process reduces barriers to entry for manufacturers, promotes competition, and speeds up biosimilar launches, further entrenching the global biosimilars market's growth path.
What Impact Does AI have on Biosimilar Approval Timelines and R&D costs?
AI is revolutionizing biosimilar development by enhancing biologic characterization, process optimization, and predictive analytics. Artificial intelligence-based machine learning models scrutinize intricate biologic structures, enhancing bio similarity evaluations and minimizing comparability study time. This results in accelerated biosimilar approval times and reduced R&D expenses, while promoting market competitiveness.
A January 2022 collaboration between Biogen and Insilico Medicine is a significant example. Global biotech giant Biogen has incorporated machine learning models and Insilico Medicine's AI-powered predictive analytics to speed up biologic characterization and automate the biosimilar development process. R&D costs fall by 50% and the time taken to receive regulatory approvals shortens when AI systems determine complex protein structures, optimize comparison studies and enhance manufacturing procedures. AI-based protein modeling platforms analyze molecular structures to predict the stability and efficacy of biosimilars, enabling more efficient manufacturing processes by reducing trial-and-error experiments and optimizing formulation development.
Moreover, AI enhances pharmacovigilance and regulatory compliance through automation of adverse event detection with the use of real-time analysis from electronic health records and social media. The regulatory authorities, such as the FDA and EMA, are implementing AI to monitor post-markets, and the biosimilars have to meet standards for safety and efficacy, enhancing confidence and adoption.
In January 2024, AION Labs, an Israeli firm that applies AI and machine learning to enhance drug discovery, launched a new firm named TenAces Biosciences. The new company is aimed at the discovery of molecular glues—small molecules that enable protein-protein interactions and enables therapeutic effects and facilitates the treatment for those diseases which were considered untreatable previously. With the application of ML, the company focuses on identifying those molecular glues which can help bind with E3 ubiquitin ligases systematically.
Market snapshot - 2025-2032
Global Market Size
Largest Segment
Monoclonal Antibodies
Fastest Growth
Insulin
Growth Rate
16.4% CAGR
Global Biosimilars Market ($ Bn)
Country Share by North America (%)
To get more reports on the above market click here to Buy The Report
Biosimilars Market Segments Analysis
The global biosimilars market is segmented based on type, application, end use, and region. In terms of type, the market is grouped into monoclonal antibodies, insulin, erythropoietin, and growth hormones. Based on application, the market is segmented into oncology, autoimmune diseases, diabetes, and chronic inflammatory diseases. In terms of end use, the market is grouped into hospitals, clinics, homecare, and research institutions. By manufacturer, it is categorized into contract research & manufacturing services and in-house. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Central & South America and the Middle East & Africa.
What value-added features have been introduced in mAb biosimilar therapies?
As per the global biosimilars market forecast, the monoclonal antibody (mAb) segment is dominating the biosimilars market share due to their efficacy, widespread application, and cost-effectiveness. These find their major applications in oncology, autoimmune disorders, and inflammatory conditions, providing cost-effective alternatives to costly biologics. The clearance and extensive use of trastuzumab biosimilars in HER2-positive breast cancer is a significant example of monoclonal antibody (mAb) biosimilars taking over the market. As cheaper alternatives to Roche's Herceptin, other companies, such as Samsung Bioepis, Biocon, and Amgen, have developed and marketed successful trastuzumab biosimilars (e.g., Ogivri, Herzuma, and Kanjinti). Since they are cheaper and offer similar safety and efficacy, targeted cancer therapy is now available everywhere. The FDA and EMA's marketing clearances simplified market entry, especially for increasing use of mAb biosimilars in cancer.
However, with the increasing incidence of diabetes globally, insulin is one of segment with the highest growth rate. Big pharma players such as Novo Nordisk and Eli Lilly are designing novel solutions in response to the increased demand for more efficient and convenient insulin administration for patients. Novo Nordisk's once-weekly insulin Icodec, for example, makes the lives of diabetic patients more convenient as it decreases injection frequency and makes adherence easier.
How are Biosimilars Revolutionizing Cancer Treatment in Oncology?
Oncology is the largest segment of Biosimilars market since biosimilars are available at a lower cost than innovative biologics and there are vast numbers of cancer patients. Prices have been reduced, and cancer treatment has been made affordable and accessible with the introduction of them in the oncology market. Additionally, since cancer exhibits high incidence and prevalence globally, the health care systems across the world are making cutting the burden of cancer through use of cost-effective therapeutic regimens a top priority.
According to the International Agency for Research on Cancer (IARC) estimates, by the year 2040, the cancer burden is anticipated to rise to 27.5 million new cases of cancer and 16.3 million cancer-related deaths worldwide. Growing numbers of cancer cases are poised to drive demand for advanced cancer drugs for treating patients successfully.
However, diabetes is an emerging field of application which is increasingly common in aging, ill diets, and unhealthy living patterns. Continuous glucose monitoring systems (CGMSs) and smart insulin pens are transforming the field of diabetes. For maximizing patient improvement and minimizing risk from diabetes-related complications, the digital insulin pen offered by Eli Lilly, for instance, synchronizes with CGMSs in real-time glucose displays.
Which Healthcare Setting Dominates the Biosimilars Market?
According to the global biosimilars market report, hospitals play a crucial role in the prescribing of complex biologic drugs, especially for chronic diseases such as diabetes, autoimmune disease, and cancer. Thus, the segment dominated the market. Cost savings and incorporation of biosimilars into treatment regimens are among the aspects driving hospital adoption.
Hospitals were responsible for more than 60% of the global biosimilar use, since most biosimilar therapies, such as monoclonal antibodies (such as Rituximab and Trastuzumab), must be given intravenously and under close supervision, which is optimally achieved in a hospital. Moreover, hospital control in this market is reinforced by government and commercial insurance policies that prefer biosimilars in hospital formularies because they are cheaper than original biologics.
Whereas, with patient requests for simplicity, remote monitoring, and self-administered biologics, the homecare category is expanding rapidly. In-home treatments for chronic diseases such as diabetes and autoimmune diseases are being selected by patients as telemedicine and wearable injectors increase in popularity. Self-injected monoclonal antibody therapy and insulin pens, for instance, are increasing and lowering hospitalization rates.
Global Biosimilars Market By Type (%)
To get detailed analysis on other segments, Request For Free Sample Report
Biosimilars Market Regional Insights
How Legislative Support and Expiring Patents Drive Biosimilar Growth in North America?
As a result of strong legislative backup, growing healthcare expenditure, and upcoming biologic patents expirations, North America has the majority of the biosimilars market globally. The regulatory measures such as the Biologics Price Competition and Innovation Act (BPCIA) have supported rapid approvals, while rising need for inexpensive medicines and the presence of big pharmaceutical corporations further accelerate the region's supremacy in biosimilar adoption and development.
United States Biosimilars Market
- The U.S. FDA Biosimilar Pathway has moved market development more rapidly by streamlining and speeding up approval.
- Biosimilars are increasingly utilized by hospitals and clinics to reduce treatment expense, particularly for autoimmune conditions and cancer.
- As a result of exclusivity loss for top-selling biologics such as Remicade and Humira, biosimilar producers can bring more affordable versions to the market, driving competition and affordability.
- Cancer, immunology, and ophthalmology biosimilar franchises are growing through players such as Coherus BioSciences, Alvotech, and Biocon Biologics.
- Three years after launch, biosimilars now represent nearly 60% of the molecular volume in the US.
- With cost-saving reimbursement mechanisms, non-340B clinics are more predicted to adopt biosimilars earlier than 340B clinics.
Canada Biosimilars Market
As of March 2024, there are 56 approved biosimilars for 18 reference biologics in Canada, and this is changing the North American biosimilars market outlook.
Why Europe Leads in Biosimilars Adoption and Regulatory Support?
The Europe biosimilars market is experiencing rapid growth, driven by robust healthcare policies, a well-established regulatory framework, and early adoption. The European Medicines Agency (EMA) has approved several biosimilars, fostering competition and reducing healthcare costs. Leading companies such as Polpharma Biologics, Bioeq, and Formycon specialize in immunology, ophthalmology, and oncology, further strengthening the market.
Italy Biosimilars Market
- With better uptake of affordably priced biologics and regulatory reforms, Italy can take over the biosimilars market.
- A probe into suspected collusion by Novartis, Roche's Genentech, Biogen, and Samsung Bioepis to slow down Byooviz, affecting patient access and healthcare spending, was initiated by Italy's antitrust authority in June 2024.
UK Biosimilars Market
- By means of medical professional training and NHS cost-containment initiatives, the UK promotes the uptake of biosimilars.
- High switch rates are a consequence of the National Institute for Health and Care Excellence's (NICE) encouragement of biosimilar switching.
- The UK is a powerful setting for the creation of biosimilars in immunology and cancer because it has effective licensing processes and a favorable market.
How Cost-Conscious Consumers are Boosting Biosimilar Adoption in Asia?
Asia-Pacific is emerging as a key player in the global biosimilars market, driven by rising healthcare demands, cost-conscious consumers, and government policies promoting affordable biologics. Countries like China, Japan, and South Korea have implemented fast-track approval processes and streamlined regulatory systems, accelerating market expansion and increasing access to cost-effective treatments.
South Korea Biosimilars Market
A December 2024 report states testing of 24 biosimilars produced by South Korean companies and spread across multiple regions. Out of those, 5 biosimilars were in the re-registration stage, with an estimated target of 10 areas of therapy and 11 were monoclonal antibodies (mAbs).
Japan Biosimilars Market
Japan's biosimilars market expansion is fueled by major industry developments, including Teva's proposed divestment of its joint venture with Takeda to JKI in December 2024, restructuring the industry.
Global Biosimilars Market By Geography
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Biosimilars Market Dynamics
Drivers
Rising Prevalence of Chronic Diseases
- The growing prevalence of chronic diseases like cancer, diabetes, and autoimmune diseases is propelling the need for cheap biologic treatments. Biosimilars ensure cheaper substitutes to pricey biologics, enhancing patients' access to life-sustaining medicines. This surging demand for long-term therapeutic solutions continues to boost uptake for biosimilar drugs.
- For instance, the FDA approved Merilog (insulin aspart-szjj) in February 2025 as the first biosimilar of insulin aspart, with the view to providing additional treatment options to diabetic patients. In the field of psoriasis and psoriatic arthritis, several ustekinumab biosimilars have been approved across regions. Such approvals enhance treatment options access among patients with psoriasis plaque and psoriatic arthritis.
Rising Demand for Cost-Effective Biologics
- With rising healthcare expenditures, the need for affordable substitutes to branded biologics is increasing. Biosimilars provide substantial savings to healthcare systems, rendering costly treatments more accessible. When doctors become more aware of them and hospitals start using them more frequently, it helps increase their adoption in the healthcare system. As a result, they become more available and accessible to patients worldwide.
- This is especially important in treating cancer (oncology), immune system disorders (immunology), and long-term illnesses (chronic diseases). Since biosimilars are more affordable alternatives to expensive biologic drugs, their wider acceptance helps in expanding treatment options and making critical medications more affordable and accessible to more patients.
Restraints
Complex and Stringent Regulatory Approval Processes
- Biosimilar undergo rigorous regulatory evaluations to prove similarity in safety, efficacy, and quality with reference biologics. The diverse approval requirements in different countries introduce delays and enhance compliance expenses. The intricate regulatory environment presents a challenge to biosimilar manufacturers, hindering product launches and limiting market reach.
Strong Market Dominance of Biologic Innovators
- Established pharmaceutical companies with patented biologics have significant market control, making it difficult for biosimilars to gain traction. These companies use aggressive pricing strategies, legal patents, and brand loyalty to keep dominating. Patent litigation and exclusivity extensions further postpone biosimilar entry, constraining competition and retarding the global biosimilars market growth.
Request Free Customization of this report to help us to meet your business objectives.
Biosimilars Market Competitive Landscape
Global biosimilars market is highly competitive, with major pharmaceutical and biotech companies actively expanding their portfolios. The leading biosimilar companies invest in R&D, strategic alliances, and regulatory clearance to capture market share. Some of the notable contributors include Pfizer, Novartis (Sandoz), Amgen, Biocon Biologics, Samsung Bioepis, and Celltrion. These players use cutting-edge manufacturing, biosimilar interchangeability strategies, and competitive pricing to battle in the market. Some of the upcoming players such as Alvotech, Coherus BioSciences, and Polpharma Biologics are also emerging, making a difference through innovation and affordability. As biosimilar adoption increases, competition intensifies, fostering market growth and affordability of biologic treatments globally.
Top Players in Biosimilars Market
- Biocon Biologics (India)
- Samsung Bioepis (South Korea)
- Celltrion (South Korea)
- Sandoz (Switzerland)
- Fresenius Kabi (Germany)
- Teva Pharmaceuticals (Israel)
- Amgen (USA)
- Mylan (USA)
- Coherus BioSciences (USA)
- Alvotech (Iceland)
- Polpharma Biologics (Poland)
- Stada Arzneimittel (Germany)
- Accord Healthcare (United Kingdom)
- Formycon (Germany)
- Pfizer (USA)
Recent Developments in Biosimilars Market
- In December 2024, Biocon Biologics received U.S. FDA approval for Yesintek (ustekinumab-kfce), a biosimilar for chronic inflammatory conditions like plaque psoriasis and Crohn's disease. The approval strengthens Biocon's presence in the U.S. market, providing an affordable option to branded biologics, and solidifying the company's position in making global biosimilar accessibility and affordability.
- In October 2024, Accord Healthcare had the European Medicines Agency (EMA) approve its biosimilar Imuldosa (ustekinumab-srlf). This biosimilar is indicated for the treatment of chronic inflammatory diseases, such as plaque psoriasis and Crohn's disease. The approval reinforces Accord Healthcare's position in the Europe biosimilars market, driving competition and broadening treatment access for patients.
- In September 2024, Fresenius Kabi gained EMA approval for Otulfi (ustekinumab-aauz), a biosimilar of plaque psoriasis, psoriatic arthritis, and Crohn's disease. The milestone enhances the company's biosimilar portfolio in Europe, enhancing competition and affordability of critical biologic therapies, favoring patients suffering from autoimmune and inflammatory diseases.
Biosimilars Key Market Trends
What Impact Does AI have on Biosimilar Approval Timelines and R&D costs?
AI is revolutionizing biosimilar development by enhancing biologic characterization, process optimization, and predictive analytics. Artificial intelligence-based machine learning models scrutinize intricate biologic structures, enhancing bio similarity evaluations and minimizing comparability study time. This results in accelerated biosimilar approval times and reduced R&D expenses, while promoting market competitiveness.
A January 2022 collaboration between Biogen and Insilico Medicine is a significant example. Global biotech giant Biogen has incorporated machine learning models and Insilico Medicine's AI-powered predictive analytics to speed up biologic characterization and automate the biosimilar development process. R&D costs fall by 50% and the time taken to receive regulatory approvals shortens when AI systems determine complex protein structures, optimize comparison studies and enhance manufacturing procedures. AI-based protein modeling platforms analyze molecular structures to predict the stability and efficacy of biosimilars, enabling more efficient manufacturing processes by reducing trial-and-error experiments and optimizing formulation development.
Moreover, AI enhances pharmacovigilance and regulatory compliance through automation of adverse event detection with the use of real-time analysis from electronic health records and social media. The regulatory authorities, such as the FDA and EMA, are implementing AI to monitor post-markets, and the biosimilars have to meet standards for safety and efficacy, enhancing confidence and adoption.
In January 2024, AION Labs, an Israeli firm that applies AI and machine learning to enhance drug discovery, launched a new firm named TenAces Biosciences. The new company is aimed at the discovery of molecular glues—small molecules that enable protein-protein interactions and enables therapeutic effects and facilitates the treatment for those diseases which were considered untreatable previously. With the application of ML, the company focuses on identifying those molecular glues which can help bind with E3 ubiquitin ligases systematically.
How do startups contribute to the competitive landscape of the market?
The global biosimilars industry has grown tremendously, fueled by the demand for affordable substitutes for biologic treatments. Startups are at the center of this action, bringing innovative products and competitive offerings.
- Established in 2013, Arven Pharmaceuticals is a Turkish pharma firm in Istanbul. Being a part of the Toksöz Group, Arven develops and manufactures high-technology inhaler and biotechnology products, with expertise in complex biosimilars for international markets, including the EU and U.S. Fraven is a biosimilar of Filgrastim, a granulocyte colony-stimulating factor that increases the production of white blood cells. It is mainly applied to cure neutropenia, a condition of low neutrophil counts, usually caused by chemotherapy. By increasing neutrophil levels, Fraven decreases the risk of infection in cancer patients undergoing treatments.
- Founded in 2013 by Róbert Wessman, Alvotech is an Icelandic biopharmaceutical company specializing in the development and production of biosimilars. One of its biosimilar is Simlandi, which is the high-dose form of Humira (adalimumab), utilized to treat autoimmune disorders like rheumatoid arthritis and Crohn's disease. Through its replication of the therapeutic action of Humira at a more affordable price, Simlandi makes treatment options available to patients and relieves patients of economic pressure. Moreover, Alvotech spent more than $1 billion in developing a world-class manufacturing facility in Reykjavik, Iceland. All biosimilar development processes are, therefore, under the complete realization of this vertical integration, from cell line development to commercial production.
- Established by David Anchel and Arturo Elizondo in 2015, The EVERY Company (formerly Clara Foods) is an American biotech company that's pioneering animal-free proteins through yeast fermentation. They convert sugar into proteins that substitute for animal-based ones, which makes them sustainable and restricts factory farming. Their key innovation, animal-free egg whites, replicates the functional properties of conventional egg whites to be applied to vegan-friendly products. They also produce bioidentical pepsin, a previously animal-sourced enzyme that offers a viable, ethical answer for pharmaceutical companies and shows them committed to revamping animal-dependent processes.
- Founded in 2015 by genomicist Jun Wang, iCarbonX is a Chinese biotechnology company that integrates genomics with other health-related data to create a comprehensive digital representation of human health. A cornerstone of iCarbonX's offerings is their digital health management platform, Meum, developed in collaboration with their Digital Life Alliance partners. This platform aggregates multi-omics data, including genomics, proteomics, and metabolomics, to deliver tailored health insights and recommendations to users. A notable breakthrough in their R&D is the establishment of a one-stop multi-omics laboratory. This facility enables comprehensive research and development across various biological fields, such as genomics, proteomics, immunomics, microbiome studies, and metabolomics.
How will Next-generation Biologics Shape the Future of Biosimilars?
The growing global biosimilars market share is facilitated by patent expiry of key biologic medicines, increasing healthcare costs, and an increase in the demand for affordable therapies. Moreover, increased competition is being driven by regulatory support and advancements in biomanufacturing. With wider acceptance of biosimilars, there is more scope for market penetration, thereby resulting in cost savings and greater accessibility to life-extending treatments among patients. Such a transition helps make healthcare sustainable globally.
- Short Term: Regulatory bodies such as the FDA and EMA are simplifying biosimilar approval procedures, resulting in more market entries. Faster approvals encourage competition, driving down costs and expanding accessibility. Healthcare providers and payers are more inclined to adopt biosimilars, causing a surge in market penetration and reshaping pricing strategies for both originator biologics and biosimilars.
- Mid Term: The biosimilars market trend of AI-driven analytics and digital biomanufacturing enhance biosimilar development efficiency, reducing production costs and time-to-market. Sophisticated bioprocessing methods enhance biosimilar quality and scalability. Greater physician and patient confidence translate into broader adoption, especially in oncology, immunology, and chronic disease management. As a result, biosimilars are key to global healthcare cost savings.
- Long Term: As biosimilars gain global acceptance, emerging markets experience increased adoption due to improved regulatory harmonization. Patent cliffs and ongoing innovation propel new competitors, heightening rivalry. Personalized medicine and next-generation biologics shape biosimilar development, with companies targeting value-add enhancements like improved delivery systems, guaranteeing long-term expansion and market viability.
Biosimilars Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global biosimilars market research is highlighting its revolutionary transformation, fueled by patent expiration, regulatory encouragement, AI innovation, and the emergence of innovative startups. As biosimilars become increasingly accepted around the world, they offer affordable substitutes for costly biologics, driving greater accessibility for patients and minimizing healthcare costs. AI-driven drug development and biomanufacturing improvements are streamlining approvals, reducing R&D expense, and improving biosimilar quality.
In addition, startups are also leading the way in market growth, bringing new technologies and promoting competitive product development. In the future, next-generation biologics and personalized medicine will drive biosimilar development, creating long-term sustainability. With continuous innovation and wider uptake, biosimilars will transform healthcare worldwide by providing affordability, innovation, and better patient outcomes.
| Report Metric | Details |
|---|---|
| Market size value in 2023 | USD 11.39 Billion |
| Market size value in 2032 | USD 41.63 Billion |
| Growth Rate | 15.49% |
| Base year | 2024 |
| Forecast period | 2025-2032 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on Biosimilars Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on Biosimilars Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the Biosimilars Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Biosimilars Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Biosimilars Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Biosimilars Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
